The global automated insulin delivery systems market size was USD 0.7 Bn in 2022 and is likely to reach USD 1.7 Bn by 2031, expanding at a CAGR of 9.72% during 2023–2031. The market is propelled by the rising cases of diabetes across the globe.
Rising problems associated with the modern sedentary lifestyle such as obesity and diabetes is propelling the demand for automated insulin delivery systems. The launch of insulin pumps and pen devices has further promoted their use. Obesity is one of the most prominent factors responsible for the onset of diabetes. Thus, the increase in the number of obese people is anticipated to largely contribute to the market growth of automated insulin delivery systems during the projection period.
- As per the report published in May 2022 by World Health Organization (WHO), there are approximately 2 billion adults that are overweight, while nearly 650 million people are suffering from obesity. It is estimated that if the current rate continues, there will approximately be 2.7 billion overweight adults and over 1 billion obese people by the year 2025.
The automated insulin delivery system is a technological solution for people who are suffering from diabetes and require intensive insulin therapy. It helps such individuals manage their blood-sugar levels more effectively than the conventional means. This solution combines the glucose pump and a continuous glucose monitor (CGM) to automatically administer insulin delivery and dosage based on real-time glucose readings.
The goal of an automated insulin delivery system is to mimic the functions of a healthy pancreas by providing the right amount of insulin at the right time, as per the body’s requirement. It reduces the burden of diabetes management and helps prevent high or low-blood sugar episodes. While the automated insulin delivery system provides significant control over diabetes management, regular healthcare consultations are necessary to ensure good health and optimal performance of the device.
The market report finds that the COVID-19 pandemic has fueled the automated insulin delivery systems market. People with diabetes have weaker immune systems and are more prone to serious health complications than normal people. As a result, the pandemic led to growth in the overall insulin intake of individuals, thereby increasing the demand for different forms of insulin delivery systems.
Automated Insulin Delivery Systems Market Dynamics
Major Drivers
Increasing global prevalence of diabetes is expected to drive the market during the forecast period. The modern lifestyle has several habits in daily life that are unhealthy and hamper the sustainability of the human body. Severe cases of diabetes can often lead to limb amputations.
The automated insulin delivery systems offer advanced and convenient treatment options to enhance the quality of life of such individuals. It provides continuous glucose monitoring and automated insulin delivery. This is projected to have a positive impact on the overall market growth.
-
As per the Centers for Disease Control (CDC), around 37.3 million people in the United States (i.e. 11.3% of the total US population) had diabetes in 2019. In 2020, diabetes became the eighth leading cause of death in the country.
Rising awareness for active diabetes management is anticipated to be a key factor in propelling the growth of the market. The automated insulin delivery systems offer precise and personalized insulin delivery, reducing the burden of manual diabetes management. By automating the insulin administration based on the real-time readings of glucose levels from the sensor, these systems enable individuals with diabetes to better manage their condition and improve overall health outcomes.
Existing Restraints
High cost of automated insulin delivery systems is likely to impede market growth due to the availability of other cost-effective alternatives. It limits the affordability for patients belonging to low-income and mid-income households. The expensive price prevents the widespread adoption of these systems. Lowing the cost and increasing affordability can help overcome this constraint and impact the market positively. Further, issues associated with the accessibility of medical devices to manage diabetes and treatment complications during medical imaging of the patient are likely to affect the market.
- As per the study published by the National Institute of Health in October 2022, people with diabetes often face challenges in getting their continuous glucose monitor (CGM) devices, owing to inconsistency problems in supply and reordering. In addition, they face problems in medical imaging of certain scans such as MRIs and computed tomography scans, as they have to remove their pumps and CGM systems every time.
Emerging Opportunities
Development of technologically advanced insulin delivery systems that are cost-effective is expected to provide substantial growth opportunities for the market. The advanced technology enables precise and personalized insulin delivery and reduces the burden of diabetes management by automating the insulin delivery process.
The availability of these systems at affordable prices makes them accessible to a larger patient population. Moreover, innovation and affordability have the potential to attract more investment, leading to further growth.
- For instance, as per the report published by American Diabetes Association in 2022, the results of CREATE trial showed that the use of open-source automated insulin delivery (AID) systems is not only safe but also highly effective for people with type-1 diabetes. It can effectively make the life of a diabetic person easier by combining the continuous glucose monitor (CGM), an insulin pump, and an algorithm to automatically regulate the insulin delivery after every five minutes, keeping the level of glucose within the specified range.
Scope of the Automated Insulin Delivery Systems Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Automated Insulin Delivery Systems Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Pens, Pen Needles, Insulin Syringes, Insulin Pumps, and Others), Application (Type I Diabetes and Type II Diabetes), End-user (Hospitals, Clinics, and Home Care)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Abbott; Johnson & Johnson Services, Inc.; BD; BIGFOOT BIOMEDICAL, INC.; Biocon; Medtronic; DreaMed Diabetes, Ltd.; F. Hoffmann-La Roche Ltd.; Lilly; Novo Nordisk A/S; Sanofi; Tandem Diabetes Care, Inc; WOCKHARDT; and Insulet Corporation.
|
Automated Insulin Delivery Systems Market Segment Insights
Type Segment Analysis
Based on type, the automated insulin delivery systems market is divided into pens, pen needles, insulin syringes, insulin pumps, and others. The pens segment holds the dominant share of the market due to its affordability, portability, and user-friendly design.
These pens are available in disposable and reusable variations, as per the need of the patient. With their simple mechanism and pre-filled insulin cartridges, pens offer a user-friendly solution for insulin delivery and reduce the risk of any errors.
The insulin pump segment is expected to expand at a significant growth rate as they offer continuous subcutaneous insulin infusion. They provide constant basal insulin doses, as well as have the ability to deliver bolus doses post meals.
This helps the individual maintain tight glycemic control, maintain sugar levels in the body, and track the data. These devices cater to the diverse needs and preferences of individuals with diabetes, offering flexibility, accuracy, and improved quality of life.
Application Segment Analysis
On the basis of application, the global market is segregated into type I diabetes and type II diabetes. The type II diabetes segment is projected to register a substantial CAGR during the forecast period due to the increasing prevalence of diabetes globally.
As type II diabetes is characterized by insulin resistance, insulin delivery systems provide a convenient and effective method for managing blood glucose levels. The automated insulin delivery systems enable continuous blood glucose monitoring and automated insulin delivery, reducing the risk of health complications.
End-User Segment Analysis
On the basis of end-user, the automated insulin delivery systems market is segmented into hospitals, clinics, and home care. The home care segment is expected to drive the market during the assessment period owing to the increasing preference for managing diabetes from the comfort of homes.
Automated insulin delivery systems provide individuals with greater control over their diabetes management, allowing for continuous monitoring and adjustment of insulin levels. This convenience has led to significant adoption of these systems in home care settings.
The hospitals segment is projected to register a considerable CAGR during the forecast period as they offer the advantage of precise insulin dosing, reduced risk of human error, and intensive care facilities. The hospitals have a large number of patients with varying insulin requirements. The automated insulin delivery systems streamline the process and enable healthcare professionals to provide personalized care effectively.
Regional Outlook
In terms of region, the global automated insulin delivery systems market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period due to the rise in the diabetic population and unhealthy lifestyle choices.
Furthermore, the region has advanced significantly in terms of integrating modern-age technology and innovative medical devices. It has expanding infrastructure that leads to the growing adoption of innovative measures of healthcare that are highly effective. These factors are anticipated to further boost the growth of the market in North America.
Asia Pacific is expected to have significant growth in the market owing to its increasing population facing different diabetic conditions. The large population leads to the growth of diabetic as well as geriatric populations. Numerous individuals have lower immunity owing to a lack of effective access to healthcare in rural areas. They require an intensive healthcare regime. The growth in the number of such individuals is likely to lead to an increased demand for automated insulin delivery systems in this region.
Segments
The automated insulin delivery systems market has been segmented on the basis of
Type
- Pens
- Pen Needles
- Insulin Syringes
- Insulin Pumps
- Others
Application
- Type I Diabetes
- Type II Diabetes
End-user
- Hospitals
- Clinics
- Home Care
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Abbott
- Johnson & Johnson Services, Inc.
- BD
- BIGFOOT BIOMEDICAL, INC.
- Biocon
- Medtronic
- DreaMed Diabetes, Ltd.
- F. Hoffmann-La Roche Ltd.
- Lilly
- Novo Nordisk A/S
- Sanofi
- Tandem Diabetes Care, Inc
- WOCKHARDT
- Insulet Corporation
Competitive Landscape
Key players competing in the global automated insulin delivery systems market are Abbott; Johnson & Johnson Services, Inc.; BD; BIGFOOT BIOMEDICAL, INC.; Biocon; Medtronic; DreaMed Diabetes, Ltd.; F. Hoffmann-La Roche Ltd.; Lilly; Novo Nordisk A/S; Sanofi; Tandem Diabetes Care, Inc; WOCKHARDT; and Insulet Corporation
These companies develop strategies for various acquisitions, partnerships, mergers, collaborations, product launches, and production expansions to cater to customers worldwide. They have to make large investments in research & development of the healthcare system to create innovative products that are new and relevant to consumer needs. For instance,
- In March 2022, the insulin manufacturer Novo Nordisk announced the release of two new insulin pens with smart connections, the NovoPen Echo Plus and NovoPen 6. These pens have been made available on prescription for people being treated for diabetes in the United Kingdom.
- In January 2022, Insulet Corp. (based in Boston, U.S.) announced that the Food and Drug Administration (FDA) has cleared their new product, Omnipod 5. This marks the company’s expansion into the automated insulin delivery (AID) market.
Request For Customization
Enquiry Before Buying
Speak With Analyst
